Home › Calculator › NAVBQ Dividend Calculator 2026
NAVBQ Dividend DRIP Calculator 2026
2000000.00% YieldHealthcareNavidea Biopharmaceuticals, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When NAVBQ pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your NAVBQ snowball 📈
$10,000 in NAVBQ → $3.603059672953261e+54M in 10 years · $300,254,958,085,218,450,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/month
About Navidea Biopharmaceuticals, Inc. (NAVBQ) — Dividend Analysis 2026
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to advancing and commercializing specialized agents for immunodiagnosis and innovative immunotherapeutics. The company operates across two distinct segments: Diagnostic Substances and Therapeutic Development Programs. Its core technology, the Manocept platform, is designed to target the CD206 mannose receptor, which is prominently found on activated macrophages. This platform enables a variety of diagnostic imaging techniques, including single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and both intra-operative and optical-fluorescence detection methods. Beyond diagnostics, Manocept also facilitates the targeted delivery of therapeutic compounds to macrophages, addressing diseases characterized by immune system involvement and inflammation. Among its key pipeline assets, NAV3-31 has successfully completed Phase IIb clinical trials. These trials assessed the imaging repeatability, reproducibility, and stability, along with the effectiveness of Tc99m tilmanocept imaging in monitoring anti-tumor necrosis factor alpha therapy for patients with moderate to severe rheumatoid arthritis (RA). NAV3-35 is currently undergoing a Phase IIb clinical trial for RA imaging, while NAV3-33 is advancing through Phase III clinical trials, also for RA. Furthermore, NAV3-32 is participating in a Phase 2b trial specifically for RA-involved joints. The company is also exploring the utility of Tc99m tilmanocept in other therapeutic areas, such as cardiovascular conditions, Kaposi's sarcoma, tuberculosis, and various other immunotherapeutic applications. Originally established as Neoprobe Corporation, the company officially adopted the name Navidea Biopharmaceuticals, Inc. in January 2012. Founded in 1983, its corporate headquarters are situated in Dublin, Ohio. In a significant corporate development, Navidea Biopharmaceuticals, Inc. initiated voluntary reorganization proceedings under Chapter 11 with the U.S. Bankruptcy Court for the District of Delaware on October 1, 2025.
Compare NAVBQ with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full NAVBQ DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open NAVBQ position with:
🌍 NAVBQ Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold NAVBQ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1600000.00% | 1599997.20% | $160,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1825000.00% | 1824997.20% | $182,500,000 / yr |
| 🇨🇦 TFSA | 0% | 2000000.00% | 1999997.20% | $200,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 1500000.00% | 1499997.20% | $150,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 1700000.00% | 1699997.20% | $170,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1472500.00% | 1472497.20% | $147,250,000 / yr |
| 🇫🇷 FR Taxable | 30% | 1400000.00% | 1399997.20% | $140,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 NAVBQ Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 NAVBQ Dividend Payment Schedule
NAVBQ pays quarterly — 4 times per year. Next ex-div: TBD.
📊 NAVBQ vs Healthcare Benchmarks
How NAVBQ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for NAVBQ sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ NAVBQ Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| J-Other | 2023-11-27 | 64,289 | $0.10 | $6.7K | ||
| J-Other | 2023-11-27 | 2,270 | $0.00 | $2.00 | ||
| J-Other | 2023-11-27 | 2,400 | $0.16 | $384.00 | ||
| A-Award | 2023-11-16 | 416,667 | — | — | ||
| A-Award | 2023-11-16 | 200,000 | — | — | ||
| A-Award | 2023-11-16 | 416,667 | — | — | ||
| A-Award | 2023-11-16 | 275,000 | — | — | ||
| A-Award | 2023-07-11 | 250,000 | — | — | ||
| A-Award | 2023-06-29 | 12,200,000 | $0.09 | $1.07M | ||
| A-Award | 2023-06-05 | 11,508,672 | $0.00 | $11.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where NAVBQ earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the NAVBQ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Navidea Biopharmaceuticals, Inc. (NAVBQ) is currently trading at $0.00, 100% below its 52-week high. The current dividend yield is 2000000.00% based on an annual payout of $2.00 per share.
NAVBQ (Navidea Biopharmaceuticals, Inc.) — 2000000.00% Dividend Yield Analysis
Navidea Biopharmaceuticals, Inc. (NAVBQ) is a healthcare stock currently trading at $0.00 with a dividend yield of 2000000.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (2000000.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.